Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Aberforth Smaller Companies Trust appoints Roy Davis as non-executive director, audit committee member

Aberforth Smaller Companies Trust appoints Roy Davis as non-executive director, audit committee member

BitgetBitget2026/09/29 15:48
  • Aberforth Smaller Companies Trust appointed Roy Davis as independent non-executive director, effective Oct. 21, 2026.
  • Davis also joins the audit committee on the same date.
  • He is non-executive chair of Inspiration Healthcare Group, Surgical Innovations Group, Galton Group; former chair of Medica Group.
  • Executive background includes CEO roles at Optos, Gyrus Group; former vice president at Arthur D. Little.
  • Davis will step down as a non-executive director at Futura Medical on Oct. 20, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aberforth Smaller Companies Trust plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609291147PR_NEWS_PRUKDSCX_0097) on September 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion

Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.

智通财经•2026/11/09 23:57